Clinical Trials for Recurrent Chronic Myelomonocytic Leukemia

Find clinical trials for recurrent chronic myelomonocytic leukemia. Discover research opportunities and treatment options in your area.

10 Active Trials Found

Showing 10 trials on this page

Page 1 of 1

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

NCT ID: NCT04375631

This clinical trial is investigating a new treatment approach for patients with certain types of blood cancers, specifically those with relapsed or hard-to-treat forms of acute myeloid leukemia (AM...

Recruiting

Phase: PHASE1 Type: interventional Locations: Seattle, Washington, United States

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

NCT ID: NCT06928662

This clinical trial is investigating a new treatment approach for adults with certain types of blood cancers, specifically those at high risk of their cancer returning. The treatment combines a med...

Recruiting

Phase: PHASE1 Type: interventional Locations: Seattle, Washington, United States

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT ID: NCT04734990

This clinical trial is studying a new treatment combination for patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The researchers want to find out the best do...

Recruiting

Phase: PHASE1 Type: interventional Locations: Houston, Texas, United States

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

NCT ID: NCT03326921

This clinical trial is testing a new type of immunotherapy called HA-1 T cell therapy to treat patients with certain types of acute leukemia that have come back, are not responding to treatment, or...

Recruiting

Phase: PHASE1 Type: interventional Locations: Seattle, Washington, United States

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT ID: NCT06712810

This clinical trial is studying a new medication called Q702 to see how safe it is and how well it works for people with certain types of blood cancers, known as hematologic malignancies. These can...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Scottsdale, Arizona, United States, Rochester, Minnesota, United States

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

NCT ID: NCT04140487

This clinical trial is studying a combination of three drugs—azacitidine, venetoclax, and gilteritinib—to see how well they work together in treating patients with certain types of leukemia and rel...

Recruiting

Phase: PHASE1 Type: interventional Locations: Houston, Texas, United States

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

NCT ID: NCT04239157

This clinical trial is studying a medication called canakinumab to see how well it works for treating patients with certain types of blood disorders, specifically low or intermediate-risk myelodysp...

Recruiting

Phase: PHASE2 Type: interventional Locations: Houston, Texas, United States

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT ID: NCT03896269

This clinical trial is looking at a new treatment called CPX-351 for patients with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has either returned after ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Houston, Texas, United States

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

NCT ID: NCT04493138

This clinical trial is investigating a combination of two medications, azacitidine and quizartinib, to see how well they work in treating patients with certain blood disorders called myelodysplasti...

Recruiting

Phase: PHASE1 Type: interventional Locations: Houston, Texas, United States

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

NCT ID: NCT05549661

This clinical trial is studying a new drug called onvansertib to see if it is safe and effective for treating patients with chronic myelomonocytic leukemia (CMML) that has either come back after tr...

Recruiting

Phase: PHASE1 Type: interventional Locations: Rochester, Minnesota, United States

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Prostate Cancer View clinical trials → Healthy View clinical trials →

Search All Trials Browse All Conditions